Can volufiline actually fix under-eye hollowness from the outside?

What did @leeskincare7 actually say?

The creator's core claim is that persistent dark circles are often caused by "undereye hollowness" rather than pigmentation, and that a topical ingredient called volufiline can address this by prompting fat cells to plump up. They also argued that spicules (from sea sponge extract) help volufiline penetrate deeper, and that results require one to two months of consistent use.

To be precise about the product: Skin1004's Matrixyl 10 Boosting Shot Ampoule contains 5% volufiline alongside matrixyl peptides and centella asiatica. The creator is not claiming this replaces filler outright, but rather that it's "a more safer and realistic option to improve hollowness over time." That framing is worth examining seriously.

Does the science back this up?

Partially, yes. But the evidence base is thinner than the marketing suggests, and a lot of the data comes from the ingredient's manufacturer.

Volufiline is a trademarked ingredient developed by Sederma, composed of sarsasapogenin and hydrogenated polyisobutene. The mechanism is real: sarsasapogenin has been shown in vitro to stimulate adipogenesis, meaning it encourages pre-adipocyte cells to differentiate and store lipids. A Sederma-sponsored study (unpublished, cited in cosmetic ingredient databases) reported measurable volume increases in inner thigh and breast tissue with twice-daily application over 56 days. That's not under-eye tissue, and it's not independent research. A 2008 study by Sederma demonstrated adipocyte lipid accumulation in cell culture, but extrapolating that to facial fat pads in vivo is a significant leap.

On spicules: marine-derived spicules from Spongilla species have genuinely been studied as micro-delivery systems. A 2021 review in the Journal of Cosmetic Dermatology (Choi et al.) noted spicules create microchannels that improve transdermal delivery of actives. That mechanism is plausible and has more independent backing than volufiline itself.

What did they get wrong (or right)?

They got the anatomy basically right. The periorbital area does lose subcutaneous fat volume with age, a process documented in CT-based studies of facial aging (Rohrich and Pessa, 2007, Plastic and Reconstructive Surgery). Calling this "hollowness" and distinguishing it from pigmentation-driven dark circles is a clinically meaningful distinction that most skincare content ignores. Credit where it's due.

Where they overreach: describing volufiline as "clinically proven to help with volume loss" is a stretch. The clinical data available is largely manufacturer-funded, uses non-facial tissue, and isn't published in peer-reviewed journals that can be independently scrutinized. That's not proof, it's promotional data. Saying something is "clinically proven" implies a level of independent, rigorous evidence that doesn't yet exist for this ingredient in under-eye applications specifically.

The spicule-as-delivery-vehicle claim is reasonable, but spicules can also cause irritation and a compromised skin barrier in the delicate periorbital region. The creator doesn't mention that tradeoff.

What should you actually know?

If your dark circles are genuinely structural, caused by fat compartment loss and orbital bone changes, no topical is going to replicate what a hyaluronic acid filler does in a trained injector's hands. That's not a dismissal of topicals, it's just physics. A filler placed under the eye instantly restores volume in a way that a cream applied twice daily for two months cannot match in magnitude.

That said, for people who want to avoid needles or can't afford injectables, a volufiline-containing product used consistently is unlikely to harm you and may offer modest improvement. The one-to-two-month timeline the creator sets is realistic and actually more honest than most skincare content. Expecting visible results in less than four weeks from any volume-targeting topical is unrealistic.

The product mentioned also contains matrixyl (palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7), which has better independent evidence for stimulating collagen synthesis than volufiline has for adipogenesis. Gorouhi and Maibach (2009, International Journal of Dermatology) reviewed peptide evidence and found palmitoyl-based peptides showed measurable effects on skin firmness in small trials. So the formula may be doing more work through its peptide content than through volufiline alone.